Robarts Research Institute
Records under this name other than the patents Robarts Research Institute holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 5 patents it holds.
Showing 1 to 10 of 10 · Back to Robarts Research Institute
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,987,315 | Use of a Combination of Myxoma Virus and Rapamycin for Therapeutic Treatment Formerly held Term ended Term ended Apr 19, 2026 · High confidence | Term ended | Term ended Apr 19, 2026 | High confidence |
| US 7,850,960 | Methods for Regulation of Stem Cells Term ended Term ended Jan 4, 2025 · High confidence | Term ended | Term ended Jan 4, 2025 | High confidence |
| US 8,372,397 | Methods for Regulation of Stem Cells No holder on record Term ended Term ended Dec 30, 2024 · High confidence | Term ended | Term ended Dec 30, 2024 | High confidence |
| US 8,193,812 | Transceive Surface Coil Array for Magnetic Resonance Imaging and Spectroscopy Held by another company Lapsed on the fee record Ended Jun 5, 2024 · Medium confidence | Lapsed on the fee record | Ended Jun 5, 2024 | Medium confidence |
| US 8,227,440 | Use of Myxoma virus for the therapeutic treatment of cancer and chronic viral infection Term ended Term ended May 22, 2024 · USPTO record | Term ended | Term ended May 22, 2024 | USPTO record |
| US 7,799,324 | Using Undifferentiated Embryonic Stem Cells to Control the Immune System Formerly held Lapsed on the fee record Ended Sep 21, 2022 · Medium confidence | Lapsed on the fee record | Ended Sep 21, 2022 | Medium confidence |
| US 8,791,084 | Inhibition of SOX9 function in the treatment of proteoglycan-associated pathophysiological conditions Formerly held Lapsed on the fee record Ended Jul 29, 2022 · USPTO record | Lapsed on the fee record | Ended Jul 29, 2022 | USPTO record |
| US 7,582,614 | Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection Lapsed on the fee record Ended Sep 1, 2021 · USPTO record | Lapsed on the fee record | Ended Sep 1, 2021 | USPTO record |
| US 8,512,713 | Myxoma Virus Mutants for Cancer Treatment Formerly held Lapsed on the fee record Ended Aug 20, 2021 · High confidence | Lapsed on the fee record | Ended Aug 20, 2021 | High confidence |
| US 7,527,968 | Regeneration Initiating Cells Lapsed on the fee record Ended May 5, 2017 · High confidence | Lapsed on the fee record | Ended May 5, 2017 | High confidence |